3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
242
Carboplatin
137
Nivolumab
132
Gemcitabine
127
Paclitaxel
116
Cisplatin
105
Cyclophosphamide
95
Bevacizumab
94
Dexamethasone
78
Injections
75
Pemetrexed
71
Docetaxel
71
Fluorouracil
68
Capecitabine
65
Rituximab
61
Cetuximab
61
atezolizumab
59
130-nm albumin-bound paclitaxel
59
Oxaliplatin
58
Leucovorin
56
Ipilimumab
54
fludarabine
48
Lenalidomide
47
Azacitidine
40
Irinotecan
39
venetoclax
38
Fulvestrant
38
Albumin-Bound Paclitaxel
36
Prednisone
35
Trastuzumab
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
INDUSTRY
×
Histamine Antagonists
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled